|
WO2017189999A1
|
|
Hck as a therapeutic target in myd88 mutated diseases
|
|
WO2017177191A1
|
|
Sf3b1 suppression as a therapy for tumors harboring sf3b1 copy loss
|
|
WO2017136508A1
|
|
Dissociation of human tumor to single cell suspension followed by biological analysis
|
|
WO2017132574A1
|
|
Compositions and methods for screening pediatric gliomas and methods of treatment thereof
|
|
WO2017127696A1
|
|
Compositions and methods for screening and identifying clinically aggressive prostate cancer
|
|
WO2017117486A1
|
|
Compositions and methods for screening and diagnosis of prostate cancer
|
|
WO2017117474A1
|
|
Bifunctional compounds for her3 degradation and methods of use
|
|
WO2017087954A1
|
|
Compositions and methods of treating cancer
|
|
WO2017087885A1
|
|
Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
|
|
WO2017083640A1
|
|
Compositions and methods for diagnosing prostate cancer using a gene expression signature
|
|
WO2017070497A1
|
|
Methods and compositions for use of driver mutations in cll
|
|
WO2017040323A2
|
|
Stabilized peptides for covalent binding to target protein
|
|
WO2017031453A1
|
|
Isolation of antigen specific b-cells
|
|
WO2017024317A2
|
|
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017015363A1
|
|
Novel pyrimidines as egfr inhibitors and methods of treating disorders
|
|
CA2989311A1
|
|
Stabilized anti-microbial peptides
|
|
CA2990846A1
|
|
Selective degradation of wild-type dna and enrichment of mutant alleles using nuclease
|
|
WO2016210291A1
|
|
Fused bicyclic pyrimidine derivatives and uses thereof
|
|
WO2017007612A1
|
|
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2016201370A1
|
|
Combination therapy of transcription inhibitors and kinase inhibitors
|
